Hazard identification and risk assessment are based on integration of human data, primarily coming from epidemiology and clinical studies, with experimental and mechanistic studies. I will review three approaches aimed at integrating different lines of evidence: the IARC Monographs program (hazard identification for carcinogens), the Epi-Tox framework (hazard identification) and the Venice criteria (genetic risk factors), addressing their strengths and limitations, and will discuss how data integration can be applied to risk assessment.
Paolo Boffetta, MD, MPH
Dr. Boffetta is a Professor in the Department of Family, Population & Preventive Medicine at Stony Brook University and Associate Director for Population Sciences at Stony Brook Cancer Center. He graduated in Medicine from the University of Turin and obtained a Master in Public Health from Columbia University. He worked at the American Cancer Society in New York, the International Agency for Research on Cancer (World Health Organization) in Lyon, France, the German Cancer Research Center in Heidelberg, Germany, and the Icahn School of Medicine at Mount Sinai in New York. He is a Professor at the University of Bologna, Italy and holds adjunct professorship at several other universities, including Harvard and Vanderbilt. His main fields of research are cancer epidemiology and cancer prevention, with emphasis on global oncology, environmental exposures, personal behaviors, gene-environment interactions, molecular epidemiology and evidence integration. He has established and coordinated international consortia in cancer epidemiology and prevention, including ILCCO (lung cancer), INHANCE (head and neck cancer), PANC4 (pancreatic cancer), ACC (Asia Cohort Consortium), StoP (stomach cancer), and ILCEC (liver cancer).